| 2D | Two dimensional |
| 3D | Three dimensional |
| 3R | Reduce, refine, replace animal testing |
| AP | Action potential |
| AVC | Atrioventricular canal |
| Activin A | Activin group beta, form A dimer |
| BETi | Bromodomain and extraterminal family inhibitor |
| bFGF | Basic fibroblast growth factor, synonymous with FGF-2 |
| BMP-4 | Bone morphogenic protein four |
| BSA-FA | BSA-bound fatty acid |
| BSA | Bovine serum albumin |
| BoC | Body-on-a-chip |
| Cx43 | Connexin 43 gap-junction protein |
| CAD | Computer-assisted design |
| CCT | Constructed cardiac tissue |
| CF | Cardiac fibroblast |
| CHD | Congenital heart disease |
| CHIR | Small molecule Wnt activator |
| CHP | Cardiac homing peptide |
| CM | Cardiomyocyte |
| CMT | Cardiac microtissue |
| CO | Cardiac organoid |
| COVID-19 | Coronavirus disease 2019 |
| CRISPR | Clustered regularly interspaced short palindromic repeats |
| CS | Cardiac spheroid |
| CVD | Cardiovascular disease |
| DCM | Dilated cardiomyopathy |
| dECM | Decellularized ECM |
| Dex | Dexamethasone |
| Dox | Doxorubicin |
| EB | Embryoid body |
| EC | Endothelial cell |
| ECM | Extracellular matrix |
| ECT | Engineered cardiac tissue |
| EHT | Engineered heart tissue |
| EMT | Epithelial-to-mesenchymal transition |
| EndC | Endocardial cell |
| EpiC | Epicardial cell |
| ExT | Exosome therapy |
| FAO | Fatty acid oxidation |
| FDA | United States Food and Drug Administration |
| FHF | First heart field |
| FO | Fusion organoid |
| FRESH | Freeform reversible embedding in suspended hydrogel |
| GelMA | Gelatin conjugated with MA |
| HA | Hyaluronic acid |
| HCM | hypertrophic cardiomyopathy |
| HF | Heart failure |
| HTDS | High-throughput drug screening |
| HoC | Heart-on-a-chip |
| IC | Immune cell |
| ICD | Intercalated disc |
| IFN-y | Interferon-gamma |
| IGF-1 | Insulin-like growth factor one |
| IL-1β | Interleukin one beta |
| IL-6 | Interleukin six |
| iPSC-CCT | iPSC-derived CCT |
| iPSC | Induced pluripotent stem cell |
| IWP2 | Inhibitor of Wnt production two, small molecule Wnt inhibitor |
| IWR | Inhibitor of Wnt response, small molecule Wnt inhibitor |
| JCF | Juxtacardiac field |
| LPS | Lipopolysaccharide |
| LQTS | Long QT syndrome |
| MA-HA | HA conjugated with MA |
| MA | Methacrylate |
| MF | Macrophage |
| MI | Myocardial infarction |
| MMP | Matrix metalloproteinase |
| MSC | Mesenchymal stem cell |
| NO | Nitric oxide |
| OFT | Outflow tract |
| PAm | Polyacrylamide |
| PC | Pericyte |
| PCL | Polycaprolactone |
| PDA | Polydopamine |
| PDGF-BB | Platelet-derived growth factor from B dimer |
| PLGF-2 | Placental growth factor two |
| PDMS | Polydimethylsiloxane |
| PEG-RGD | PEG conjugated with RGD peptide |
| PEG | Polyethylene glycol |
| PGA | Polyglycolic acid |
| PGS | Poly(glycerol sebacate) |
| PINIPAAm | Poly(N-isopropylacrylamide) |
| PLA | Polylactic acid |
| PLGA | Poly(lactic-co-glycolic acid) |
| PMMA | Polymethylmethacrylate |
| PU | Polyurethane |
| PoMaC | Poly(octamethylene maleate (anhydride) citrate) |
| Poly(I:C) | Polyinosinic:polycytidylic acid |
| RGD | Arg-Gly-Asp peptide |
| RGDFK | Arg-Gly-Asp-Phe-Lys peptide |
| SA | Sinoatrial |
| SHF | Second heart field |
| SLA | Stereolithography |
| SQTS | Short QT Syndrome |
| SWIFT | Sacrificial writing into functional tissue |
| T3 | Triiodothyronine |
| TGF-β | Transforming growth factor-beta |
| TNF | Tumor necrosis factor, synonymous with TNF-α |
| VEGF-A | Vascular endothelial growth factor form A |
| VSMC | Vascular smooth muscle cell |
| Wnt-C59 | Small molecule Wnt inhibitor |
| Wnt | Wingless-related integration site |
| YAP | Yes-associated protein |
| YIGSR | Tyr-Ile-Gly-Ser-Arg peptide |